Tag: David Brunel

Biodesix acquires Oncimmune’s laboratory and IPN malignancy test in US

pharmanewsdaily- November 4, 2019

Biodesix, a lung cancer diagnostic solutions company, has acquired UK-based Oncimmune’s laboratory and incidental pulmonary nodule (IPN) malignancy test in the US, to expand its ... Read More